ArticleEpigenetics2026
Associations of breast DNA methylation-based measures of biological ageing with obesity-related breast cancer risk markers.
Article in Epigenetics, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Advancing age and deregulated obesity are well-established risk factors for breast cancer risk. While epigenetic ageing, a measure of biological ageing, has been linked to breast cancer risk, prior studies have mainly focused on blood-based measures. We aimed to study well-established epigenetic age estimates in normal breast tissue in relation to obesity-related metabolic markers. We analysed breast tissue from 91 cancer-free women, using DNA methylation age (mAge) clocks, including first-generation clocks (Hannum, Horvath), mortality-related clocks (Grim, Pheno), and methylation-based telomere length (DNAmTL). Pearson correlations assessed relationships among the clocks. Linear regression was used to associate mAge clocks with obesity-related blood markers (leptin, adiponectin, IGF-1, IGFBP-3), adjusting for chronological age, race, body mass index (BMI), and smoking, applying a false discovery rate threshold of 0.1. We explored effect modification by menopausal status using interaction terms. In the normal breast tissue, the strongest correlation of mAge estimates was observed between Horvath-mAge and Grim-mAge (r = 0.85). BMI was positively associated with all mAge estimates except Pheno-mAge. Older Grim-mAge and longer DNAmTL were associated with higher levels of adiponectin, IGF-1, and IGFBP-3, while older Horvath-mAge was associated only with IGF-1. Associations of DNAmTL with IGF-1 and adiponectin differed statistically by menopausal status. Epigenetic age in breast tissue, particularly Grim and DNAmTL, is associated with obesity-related metabolic markers, independent of chronological age, BMI, and smoking. Although limited by a moderate sample size, our findings indicate a potential biological pathway linking mAge-related metabolic dysregulation that may provide insight into breast cancer risk.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.